Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 4Phase NA 3Phase 3 3Phase 1/2 3Phase 4 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1HR+/HER2- Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × dalpiciclib × Clear all
NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

West China Hospital

Phase 1 Recruiting
6 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06225921 2024-03-06

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Unknown
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05515289 2023-03-10

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
30 enrolled
Breast

Breast Neoplasms

NCT05586841 2022-10-19

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Unknown
30 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡